Leila MEHDİZADEHTAPEH, Pinar OBAKAN YERLİKAYA

Endoplasmic reticulum stress and oncomir-associated chemotherapeutic drug resistance mechanisms in breast cancer tumors

Breast cancer, as a heterogenous malign disease among the top five leading causes of cancer death worldwide, is defined as by far the most common malignancy in women. It contributes to 25% of all cancer-associated deaths after menopause. Breast cancer is categorized based on the expression levels of cell surface and intracellular steroid receptors [estrogen, progesterone receptors, and human epidermal growth factor receptor (HER2)], and the treatment approaches frequently include antiestrogen, aromatase inhibitors, and Herceptin. However, the management and prevention strategies due to adverse side effects stress the patients. The unsuccessful treatments cause to raise the drug levels, leading to excessive toxic effects on healthy cells, and the development of multidrug-resistance (MDR) in the tumor cells against chemotherapeutic agents. MDR initially causes the tumor cells to gain a metastatic character, and subsequently, the patients do not respond adequately to treatment. Endoplasmic reticulum (ER) stress is one of the most important mechanisms supporting MDR development. ER stress-mediated chemotherapeutic resistance is very common in aggressive tumors. The in vitro and in vivo experiments on breast tumors indicate that ER stress-activated protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)- activating transcription factor (ATF4) signal axis plays an important role in the survival of tumors and metastasis. Besides, ER stress-associated oncogenic microRNAs (miRNAs) induce chemoresistance in breast tumors. We aimed to have a look at the development of resistance mechanisms due to ER stress as well as the involvement of ER stress-associated miRNA regulation following the chemotherapeutic regimen in the human breast tumors. We also aimed to draw attention to potential molecular markers and therapeutic targets.

Keywords:

Endoplasmic reticulum stress, unfolded protein response, multidrug resistance oncomir, breast cancer,

PDF

___

Alamolhodaei NS, 2016, CURR PHARM DESIGN, V22, P6946, DOI 10.2174/1381612822666161102100211
Andruska N, 2015, ONCOGENE, V34, P3760, DOI 10.1038/onc.2014.292
Assaraf YG, 2019, DRUG RESIST UPDATE, V46, DOI 10.1016/j.drup.2019.100645
Avril T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.72
Balaji SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155013
Baliu-Pique M, 2020, CANCERS, V12, DOI 10.3390/cancers12113271
Cai YL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0669-8
CASWELLJIN JL, 2019, NAT COMMUN, V10, DOI DOI 10.1038/S41467-019-08593-
Cava C, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1535-2
Chakravarty G, 2016, BIOCHIMIE, V124, P53, DOI 10.1016/j.biochi.2016.01.014
Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479
Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490
Chhabra R, 2011, RNA BIOL, V8, P648, DOI 10.4161/rna.8.4.15583
Cook KL, 2014, FASEB J, V28, P3891, DOI 10.1096/fj.13-247353
Davila-Gonzalez D, 2018, CLIN CANCER RES, V24, P1152, DOI 10.1158/1078-0432.CCR-17-1437
De Mattia E, 2015, DRUG RESIST UPDATE, V20, P39, DOI 10.1016/j.drup.2015.05.003
De Mattos-Arruda L, 2015, ONCOTARGET, V6, P37269, DOI 10.18632/oncotarget.5495
Deepak KGK, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104683
Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241
Dong XL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03189-z
Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
Fultang N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58864-0
Gao Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202002518
Gooding AJ, 2020, MOL CANCER RES, V18, P1257, DOI 10.1158/1541-7786.MCR-20-0067
Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
Han WY, 2020, J CANCER, V11, P2593, DOI 10.7150/jca.38449
Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0122-z, 10.1038/s41572-019-0111-2]
Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T
Hemmatzadeh M, 2020, J CELL PHYSIOL, V235, P3235, DOI 10.1002/jcp.29286
Hillary RF, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0453-1
Hotamisligil GS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a006072
Huang DS, 2016, SCI REP-UK, V6, DOI 10.1038/srep20502
Jafari SH, 2018, J CELL PHYSIOL, V233, P5200, DOI 10.1002/jcp.26379
Jiang Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00846
Katsuno Y, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau8544
Ke KL, 2017, ONCOL LETT, V14, P5994, DOI 10.3892/ol.2017.6930
Kim MR, 2009, CANCER SCI, V100, P1834, DOI 10.1111/j.1349-7006.2009.01260.x
Kong Dejuan, 2011, Cancers (Basel), V3, P716, DOI 10.3390/cancers30100716
Li NN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.119
Li X, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020404
Li XN, 2016, BIOCHEM BIOPH RES CO, V477, P768, DOI 10.1016/j.bbrc.2016.06.133
Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
Li Z, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.580251
Logue SE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05763-8
Lv C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01059-5
Lv MM, 2014, TUMOR BIOL, V35, P10773, DOI 10.1007/s13277-014-2377-z
Manie E, 2016, INT J CANCER, V138, P891, DOI 10.1002/ijc.29829
McGrath EP, 2018, CANCERS, V10, DOI 10.3390/cancers10100344
Mendes F, 2020, CANC DRUG RESIST, V3, P209, DOI [10.20517/cdr.2019.86, DOI 10.20517/CDR.2019.86]
Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167
Ming J, 2015, ONCOTARGET, V6, P40692, DOI 10.18632/oncotarget.5827
Mukerjee G, 2018, NPJ GENOM MED, V3, DOI 10.1038/s41525-018-0065-4
Najjary S, 2020, GENE, V738, DOI 10.1016/j.gene.2020.144453
O'Brien NA, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01320-8
Ortega MA, 2020, J ONCOL, V2020, DOI 10.1155/2020/9258396
Osaki M, 2019, YONAGO ACTA MED, V62, P182, DOI 10.33160/yam.2019.06.002
Ponnusamy L, 2019, CANC DRUG RESIST, V1, DOI [10.20517/cdr.2018.11, DOI 10.20517/CDR.2018.11]
Qu YD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0992-4
Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w
Rodriguez-Gonzalez FG, 2011, BREAST CANCER RES TR, V127, P43, DOI 10.1007/s10549-010-0940-x
Salaroglio IC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0967-0
Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0
Sancho-Garnier H, 2019, PRESSE MED, V48, P1076, DOI 10.1016/j.lpm.2019.09.022
Sanoff HK, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju057
Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
Shirjang S, 2019, FREE RADICAL BIO MED, V139, P1, DOI 10.1016/j.freeradbiomed.2019.05.017
Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523
Toyoda Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00208
Vasiliou Vasilis, 2008, Hum Genomics, V3, P1
Vilquin P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0515-1
Wang WY, 2018, MOL CANCER THER, V17, P1973, DOI 10.1158/1535-7163.MCT-17-0802
Wang X., 2019, CANC DRUG RESIST, V2, P141, DOI [10.20517/cdr.2019.10, DOI 10.20517/CDR.2019.10]
Wilkens Stephan, 2015, F1000Prime Rep, V7, P14, DOI 10.12703/P7-14
Wu J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0935-8
Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031
Wu Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1437-0
Xie J, 2016, BIOCHEM BIOPH RES CO, V474, P612, DOI 10.1016/j.bbrc.2016.03.002
Yamaguchi H, 2014, ONCOGENE, V33, P1073, DOI 10.1038/onc.2013.74
Yang H, 2020, ONCOGENE, V39, P5795, DOI 10.1038/s41388-020-01402-z
Yang ML, 2018, MOL MED REP, V17, P6211, DOI 10.3892/mmr.2018.8704
Yuan YL, 2016, DRUG DELIV, V23, P3350, DOI 10.1080/10717544.2016.1178825
Zedain A, 2020, J CANC TUMOR INT, V1, P9, DOI [10.9734/jcti/2020/v10i330127, DOI 10.9734/JCTI/2020/V10I330127]
Zhang LN, 2020, PHYTOMEDICINE, V78, DOI 10.1016/j.phymed.2020.153329
Zhang TT, 2019, FUTURE MED CHEM, V11, P2573, DOI 10.4155/fmc-2018-0507
Zhang XY, 2017, CLIN CANCER RES, V23, P814, DOI 10.1158/1078-0432.CCR-16-1735
Zhao TT, 2018, J CANCER, V9, P1349, DOI 10.7150/jca.22390
Zheng YF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8781690
Zhu YF, 2019, ONCOGENE, V38, P5778, DOI 10.1038/s41388-019-0846-y